COLIPSO - Co prevalence of liver disease in psoriatic disease
Research type
Research Study
Full title
A longitudinal observational study evaluating liver disease prevalence in psoriatic disease (skin and/or joint) before and after disease-modifying treatment.
IRAS ID
274846
Contact name
Laura Coates
Contact email
Sponsor organisation
University of Oxford, Clinical Trials and Research Governance
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Patients with psoriatic disease have a much higher risk of developing non-alcoholic liver disease. This causes significant impact on their life and is a difficult clinical problem as some therapies for psoriasis and arthritis may worsen the liver disease. Previously the only tests available have been blood tests (which are often normal until the liver is quite damaged) or a liver biopsy (an invasive and risky procedure which only takes a very small sample of the liver). Our colleagues have developed and tested a new type of MRI scan which can measure inflammation and scarring in the liver allowing us to study liver disease in detail.
We want to use this new technology to study the proportion of people with psoriasis who may also have associated liver disease and measure how severe this is. We will use blood, urine and stool samples to study why and how the liver disease develops in many people with psoriatic disease. We will repeat the scans and research samples after 6 months on a new treatment to see how common psoriasis treatments affect both inflammation and scarring in liver disease.
REC name
London - Bromley Research Ethics Committee
REC reference
20/LO/0616
Date of REC Opinion
14 Jul 2020
REC opinion
Further Information Favourable Opinion